Correction

This article refers to:

American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time

Article title: American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene should not replace naloxone as the primary opioid antidote at this time

Authors: Andrew I. Stolbach, Maryann E. Mazer-Amirshahi, Lewis S. Nelson and Jon B. Cole

Journal: Clinical Toxicology

Bibliometrics: Volume 61, Number 11, pages 952-955

DOI: http://dx.doi.org/10.1080/15563650.2023.228339

The authors regret that two entries in the version of the Table that was published online were transposed. The corrected version is shown below.

Table 1. Comparison of naloxone and nalmefene.

	Naloxone intranasal	Naloxone intravenous	Nalmefene intranasal
Half-life (h)^a	2.08	0.5 - 1.5	7.11
Time to peak concentration (h)	0.5	Nearly instantaneous	0.25
Inhibition constant (nM)^b	5.4	5.4	1.0
Wholesale acquisition cost ($)	$64.80 - 75/nasal administration [2-pack]	$5.27 - 23.72/mL of 0.4 mg/mL solution	$98 [2-pack]

^a Serum half-life (Not a direct measure of duration of action, but may correlate with duration of action)

^b Inhibition constant (Ki) is inversely proportional to receptor affinity, not dependent on route of administration.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.